Clinical Trial Update: Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of durvalumab and tremelimumab for relapsed/refractory germ cell tumors; the study is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysgerminoma
• Germ Cell Tumor
• Germinomatous Germ Cell Tumor
• Nonseminomatous Germ Cell Tumor
• Pineal Germ Cell Tumor
• Seminoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING